Cocrystal Pharma Shares Drop 35 percent Following Phase 2a Study Extension Announcement
| COCP Stock | USD 1.98 0.03 1.49% |
Slightly above 61% of Cocrystal Pharma's investor base is looking to short. The analysis of overall sentiment of trading Cocrystal Pharma stock suggests that many investors are alarmed at this time. Cocrystal Pharma's investing sentiment overview a quick insight into current market opportunities from investing in Cocrystal Pharma. Many technical investors use Cocrystal Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Cocrystal |
Antiviral medicines are developed using a unique structure-based drug discovery platform.
Read at finance.yahoo.com
 |
Cocrystal Pharma Fundamental Analysis
We analyze Cocrystal Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cocrystal Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cocrystal Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
Cocrystal Pharma is currently under evaluation in target price category among its peers.
Cocrystal Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cocrystal Pharma stock to make a market-neutral strategy. Peer analysis of Cocrystal Pharma could also be used in its relative valuation, which is a method of valuing Cocrystal Pharma by comparing valuation metrics with similar companies.
Peers
Cocrystal Pharma Related Equities
| MBRX | Moleculin Biotech | 8.05 | ||||
| RNXT | RenovoRx | 6.38 | ||||
| TPST | Tempest Therapeutics | 3.33 | ||||
| CYCC | Cyclacel Pharmaceuticals | 2.86 | ||||
| BDRX | Biodexa Pharmaceticals | 2.80 | ||||
| BPTH | Bio Path | 2.44 | ||||
| ALLR | Allarity Therapeutics | 1.94 | ||||
| VRAX | Virax Biolabs | 1.87 | ||||
| IKNA | Ikena Oncology | 0.66 | ||||
| AKTX | Akari Therapeutics | 0.83 | ||||
| PULM | Pulmatrix | 2.13 | ||||
| REVB | Revelation Biosciences | 2.44 | ||||
| QNRX | Quoin Pharmaceuticals | 3.39 |
Additional Tools for Cocrystal Stock Analysis
When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.